相关实验视频

Updated: Jul 17, 2026

Novel Apparatus and Method for Drug Reinforcement

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

在乌克兰PWID的随机试验中,每日口服PrEP的遵守率低,自我报告的有效性低

Kostyantyn Dumchev¹, Marina Kornilova², Olena Makarenko¹

¹Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.

The International journal on drug policy

|December 7, 2023

概括

在注射药物使用者 (PWID) 中,每日口服暴露前预防 (PrEP) 的遵守率非常低,自我报告和生物标志物结果之间存在显著差异. 这凸显了在这个人群中实现 PrEP 持续使用的挑战.

科学领域:

公共卫生公共卫生
预防传染病预防传染病
艾滋病毒/艾滋病研究研究

背景情况:

每日口服暴露前预防 (PrEP) 已证明在预防艾滋病毒传播方面具有有效性.
有限的研究已经评估了使用实验室标记在注射药物 (PWID) 的人中PrEP的坚持.

研究的目的:

评估最近在乌克兰基辅注射PWID的人群中遵守每日口服TDF/FTC PrEP.
用自我报告的措施和实验室生物标志物来比较坚持.
评估短信提醒对PrEP遵守的影响.

主要方法:

在PWID中每天口服TDF/FTC PrEP随机试验,有或没有SMS提醒.
在艾滋病毒诊所注册和启动,并在社区减少危害中心进行后续访问.
通过结构化面试,咨询,PrEP发放和用于TDF/FTC生物标志物分析的干血斑点采集进行依从性评估.

主要成果:

在199名注册的PWID中,在6个月内保持率高 (79.4%).
自我报告的坚持率很高 (77%服用>95%的剂量),但TDF/FTC代谢物的生物标志物检测率很低 (17%和25%).
只有3%的参与者显示生物标志物水平表明 PrEP 持续吸收;在短信提醒和生物标志物检测之间没有发现关联.

结论:

在活跃注射PWID的人群中,尽管咨询和短信提醒,每日口服PrEP的坚持非常低.
自我报告的坚持和验证的生物标志物数据之间存在显著的不一致.
使用生物标志物的进一步实施研究至关重要,以确定PWID是否可以实现足够的口服PrEP坚持,考虑长效注射PrEP作为替代方案.

关键词:

美国FTCtptp 这就是PWIDID的原因.准备剂的坚持 PrEP 的坚持暴露前预防暴露前预防 TFVdp 在线播放

更多相关视频

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

相关概念视频

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...